Ocular's $51.8M Revenue at -513% Margin vs. Prime's Gene-Editing Moonshot

Biotech investors weighing Ocular Therapeutix against Prime Medicine face the quintessential pipeline-versus-product dilemma. Ocular has a marketed drug, Dextenza, yet its -513% net margin and 19% revenue decline raise existential questions about its therapeutic area strategy. Prime Medicine’s Prime Editing technology, still preclinical, resembles a future-proof platform that could spawn multiple blockbusters—if the science translates. In a sector where binary events dominate, how should risk be calibrated?

Investors navigating the healthcare sector in mid-2026 face a stark choice between proven, reimbursement-anchored service providers and high-risk, high-reward biotech innovators. Two recent comparative analyses—DaVita versus Encompass Health, and Ocular Therapeutix versus Prime Medicine—illuminate the diverging value propositions across the industry. Each pairing offers a microcosm of broader trends: the tug-of-war between steady cash flows and transformative potential, the weight of government payer reliance, and the tolerance for deep losses in pursuit of breakthrough treatments.

“

In fiscal 2025, DaVita posted $13.6 billion in revenue, up 6.5% year-over-year, yet net income fell from $936.3 million to $746.8 million, squeezing margins to about 5.5%.

DaVita and Encompass Health represent the bedrock of U.S. healthcare services. DaVita’s 3,242 outpatient dialysis centers serve a captive, chronically ill population, while Encompass Health’s growing network of inpatient rehabilitation hospitals caters to an aging population with increasing needs. Both are heavily dependent on Medicare and Medicare Advantage, with government programs comprising roughly 68% of DaVita’s U.S. dialysis revenue. This creates a double-edged sword: predictable demand but acute sensitivity to reimbursement policy shifts. In fiscal 2025, DaVita posted $13.6 billion in revenue, up 6.5% year-over-year, yet net income fell from $936.3 million to $746.8 million, squeezing margins to about 5.5%. Its balance sheet is highly leveraged, with a debt-to-equity ratio that, when calculated under standard accounting, reveals total liabilities exceeding equity. Still, free cash flow of $1.3 billion underscores the cash-generating power of essential services. Encompass Health, while not detailed in the cluster, is posited as a growthier alternative—a rehabilitation specialist riding favorable demographics. The investment case here hinges on volume growth and operational leverage, with reimbursement stability as the linchpin.

At the opposite end of the spectrum lie Ocular Therapeutix and Prime Medicine—two biotechs operating at vastly different stages of maturity but united by pioneering science. Ocular already has a commercial product, Dextenza, an ocular insert generating $51.8 million in 2025 revenue. Yet sales dropped nearly 19% from the prior year, and the company posted a staggering net loss of $265.9 million, a net margin of -513%. Heavy reliance on three specialty distributors for 75% of revenue introduces concentration risk. Despite a pristine balance sheet (current ratio ~15.4, debt-to-equity ~0.1), negative free cash flow of $216.9 million signals a steady burn. Prime Medicine is even earlier stage, a clinical-stage platform company whose Prime Editing technology promises to precisely correct genetic errors like a DNA word processor. It has no commercial revenue, and its financials are not listed in the source, but the typical biotech narrative of cash consumption and capital raises applies. The bet is on a one-time cure paradigm that could disrupt vast disease categories.